Founded in 1993 through brothers Tom and David Gardner, The Motley Fool is helping millions of others gain monetary freedom through our website, podcasts, books, newspaper columns, radio screens and high-end investment services.
The highly anticipated test effects of a candidate for the AstraZeneca coronavirus vaccine (NYSE: AZN) approved by the University of Oxford arrived Monday at The Lancet, a leading medical journal. And they put the adenovirus-based candidate, AZD1222, firmly in the race to expand vaccines capable of ending the COVID-19 pandemic.
This is a giant initial trial with 1,077 healthy patients randomized to obtain a single injection of AZD1222 or a meningitis vaccine as a control. Researchers also administered a booster injection to 10 patients in azD1222 after 28 days.
In terms of security, the effects are between quite smart and wonderful. There have been no serious adverse occasions related to AZD1222, however, some patients have reported injection site pain and symptoms that may be due to a real COVID-19 infection. More than 20% of patients who gained AZD1222 reported moderate fever and fatigue.
It is too early to measure the number of COVID-19 infections in each organization to assess the effectiveness of AZD1222, but the symptoms of an immune reaction that can prevent SARS-CoV-2, the guilty COVID-19 virus, were encouraging. Antibodies against the complex protein used through SARS-CoV-2 to enter host cells peaked 28 days after injection and remained at the upper grades for a 56-day evaluation.
Oxford and AstraZeneca have already started larger Phase 3 clinical trials in Brazil, the UK and South Africa. A U.S. exam To measure the number of other people injected with AZD12222 receiving COVID-19 compared to those who won placebo will begin shortly.